Wall Street Zen Upgrades Sensus Healthcare (NASDAQ:SRTS) to “Hold”

Sensus Healthcare (NASDAQ:SRTS) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other brokerages also recently commented on SRTS. Lake Street Capital lowered their price objective on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sensus Healthcare in a report on Friday, April 4th. Finally, Maxim Group dropped their price objective on Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $11.67.

Sensus Healthcare Trading Down 3.2%

SRTS opened at $4.81 on Friday. Sensus Healthcare has a 1-year low of $4.01 and a 1-year high of $9.33. The company has a market cap of $79.10 million, a price-to-earnings ratio of 12.03 and a beta of 1.32. The company’s fifty day moving average price is $4.66 and its two-hundred day moving average price is $5.72.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The business had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million. As a group, equities analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRTS. Larson Financial Group LLC purchased a new position in shares of Sensus Healthcare in the 1st quarter worth approximately $26,000. JPMorgan Chase & Co. bought a new stake in Sensus Healthcare during the fourth quarter worth $27,000. Barclays PLC purchased a new position in Sensus Healthcare in the fourth quarter worth $35,000. BNP Paribas Financial Markets bought a new position in Sensus Healthcare in the 4th quarter valued at $47,000. Finally, Chapin Davis Inc. grew its stake in Sensus Healthcare by 50.0% in the 1st quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $71,000 after purchasing an additional 5,000 shares during the period. Hedge funds and other institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.